Literature DB >> 6638727

Collagen genes and brittle bones.

J R Shapiro, D W Rowe.   

Abstract

The heritable diseases of connective tissue are caused by known or putative defects in the synthesis of collagens, proteoglycans, glycoproteins, or attachment proteins of the extracellular matrix. Abnormal synthesis of type I collagen has been reported in several clinical variants of osteogenesis imperfecta. Because clinical classification of these variants is limited by genetic heterogenity and variable expression, biochemical criteria should be used for precise definition of the variants. Newly recognized molecular defects in osteogenesis imperfecta include the diminished formation of type I collagen and alpha-1[I] messenger RNA; abnormal synthesis or faulty assembly of alpha-2[I]; deletion or insertion of base pairs in the gene for alpha-1[I] or alpha-2[I] and failure to secrete type I procollagen; and substitution of cysteine for glycine in the triple helix. These molecular defects are characteristic of several variants. However, the molecular lesion in most cases of severe osteogenesis imperfecta has not been identified; synthesis of type I collagen and alpha-1: alpha-2 chain ratios appears to be normal. Production of an alpha-1 trimer may represent one such lesion in severe disease.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6638727     DOI: 10.7326/0003-4819-99-5-700

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  3 in total

Review 1.  Osteogenesis imperfecta: translation of mutation to phenotype.

Authors:  P H Byers; G A Wallis; M C Willing
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

Review 2.  Collagen genes and inherited connective tissue disease.

Authors:  K S Cheah
Journal:  Biochem J       Date:  1985-07-15       Impact factor: 3.857

3.  Vertebral bone mineral content in osteogenesis imperfecta.

Authors:  D Kurtz; K Morrish; J Shapiro
Journal:  Calcif Tissue Int       Date:  1985-01       Impact factor: 4.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.